Sector News

Teva Pharm to halt R&D in cancer and women’s health to cut costs

October 7, 2014
Life sciences

 

(Reuters) – Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women’s health to cut costs, though it will maintain a commercial presence in these areas.

 
The world’s biggest generic drugmaker will discontinue or divest from 14 projects in its pipeline, the Israeli company said on Monday. These projects amount to more than $150 million in R&D costs in 2015 and more than $200 million for each of 2016 and 2017.
 
These cost savings will be directed, in part, to increasing resources in Teva’s core therapeutic areas – central nervous system (CNS) and respiratory – while another part will support the company’s drive to improve efficiency.
 
The higher investment in core areas will raise R&D productivity without increasing the overall R&D budget, Teva said.
 
In women’s health and oncology, where Teva has a significant commercial presence, it said it will focus on market-ready or close-to-market products to maximize profitability. Teva said it will also continue to evaluate opportunities for commercially oriented activities and collaborations.
 
Teva’s chief executive, Erez Vigodman, said the company’s CNS and respiratory products in late-stage development are expected to generate great value.
 
“Out of the 30-plus product launches we anticipate by 2019, with a total of over $4 billion in new revenue on a risk-adjusted basis, over 20 products will be launched in these two core therapeutic areas,” he said.
 
(Reporting by Tova Cohen, editing by Louise Heavens)
 
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”